Put Options

8 transactions
Quarter Operation Price Per put puts change puts Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$120.0 - $182.95 $4.15 Million - $6.33 Million
-34,600 Reduced 73.46%
12,500 $1.58 Million
Q1 2024

May 15, 2024

BUY
$170.78 - $208.42 $4.25 Million - $5.19 Million
24,900 Added 112.16%
47,100 $8.66 Million
Q4 2023

Feb 14, 2024

BUY
$114.17 - $185.35 $924,777 - $1.5 Million
8,100 Added 57.45%
22,200 $3.99 Million
Q3 2023

Nov 14, 2023

SELL
$138.78 - $176.51 $3.84 Million - $4.89 Million
-27,700 Reduced 66.27%
14,100 $2.24 Million
Q2 2023

Aug 14, 2023

BUY
$138.42 - $180.31 $2.8 Million - $3.64 Million
20,200 Added 93.52%
41,800 $5.91 Million
Q1 2023

May 15, 2023

SELL
$154.26 - $198.1 $2.14 Million - $2.75 Million
-13,900 Reduced 39.15%
21,600 $3.64 Million
Q4 2022

Feb 14, 2023

BUY
$162.42 - $220.56 $600,954 - $816,072
3,700 Added 11.64%
35,500 $6.01 Million
Q3 2022

Nov 14, 2022

BUY
$160.42 - $256.21 $914,393 - $1.46 Million
5,700 Added 21.84%
31,800 $5.95 Million

Others Institutions Holding RGEN

About REPLIGEN CORP


  • Ticker RGEN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Medical Instruments & Supplies
  • Shares Outstandng 55,491,200
  • Market Cap $7.57B
  • Description
  • Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products....
More about RGEN
Track Ken Griffin's Portfolio

Track Ken Griffin Portfolio

Follow Ken Griffin (Citadel Advisors LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.